A Phase 1/2 Trial of the KSP Inhibitor ARRY-520 in Relapsed/Refractory Multiple Myeloma


Abstract

ARRY-520 has promising single-agent activity in heavily pretreated patients who have progressed after multiple therapies
Poster
non-peer-reviewed

A Phase 1/2 Trial of the KSP Inhibitor ARRY-520 in Relapsed/Refractory Multiple Myeloma


Author Information


PDF Share